文献速递肺外科

右中叶肺癌再评估:肺段4与肺段5肿瘤的比较

Reassessment of Right Middle Lobe Lung Cancer: Comparison of Segments 4 and 5 Tumors.
PubMed 文献 · Ann Thorac Surg · 2018-01-09

该回顾性研究纳入711例临床I期非小细胞肺癌行肺叶或双肺叶切除术患者,比较右中叶肺段4与肺段5肿瘤的预后。肺段5肿瘤患者5年总生存率和无复发生存率均显著低于肺段4肿瘤患者,且肺段5肿瘤是预后不良的独立因素,并倾向于导致更多病理性纵隔淋巴结转移。

要点

  • 肺段5肿瘤患者5年总生存率69.8% vs 肺段4的87.6%,p=0.040。
  • 肺段5肿瘤患者5年无复发生存率58.4% vs 肺段4的73.0%,p=0.029。
  • 肺段5肿瘤是预后不良的独立因素,且倾向于导致更多纵隔淋巴结转移(12.8% vs 2.3%,p=0.097)。

核心结论

  • 肺段5肿瘤患者的预后比肺段4及其他肺叶肿瘤患者更差。
  • 作者推测这是因为肺段5肿瘤导致更多纵隔淋巴结转移。
  • 肿瘤位置是右中叶肺癌患者的重要预后因素。

研究设计与样本

  • 回顾性分析了711例因临床I期非小细胞肺癌行肺叶或双肺叶切除术的患者(上叶346例,中叶82例,下叶283例)。
  • 采用log rank检验和Cox回归分析评估影响生存的因素。

主要发现

  • 肺段5肿瘤患者(n=39)的5年总生存率显著低于肺段4肿瘤患者(n=43)(69.8% vs 87.6%,p=0.040)。
  • 肺段5肿瘤患者(n=39)的5年无复发生存率显著低于肺段4肿瘤患者(n=43)(58.4% vs 73.0%,p=0.029)。
  • 多变量Cox回归分析显示肺段5肿瘤是预后不良的独立因素。
  • 肺段5肿瘤相比肺段4肿瘤倾向于导致更多病理性纵隔淋巴结转移(12.8% vs 2.3%,p=0.097)。
  • 与其他肺叶肿瘤相比,肺段4肿瘤患者预后无显著差异;但肺段5肿瘤患者预后显著且突出地更差(5年总生存率69.8% vs 82.2%,p=0.020;5年无复发生存率58.4% vs 71.4%,p=0.0071)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this study was to elucidate the clinical behavior of right middle lobe lung cancer, with focus on the tumor location. METHODS: We reviewed retrospectively 711 patients who underwent lobectomy or bilobectomy for clinical stage I non-small cell lung cancer (upper lobe, 346; middle lobe, 82; lower lobe, 283). Factors affecting survival were assessed by log rank tests and Cox regression analyses. RESULTS: The prognosis of patients with segment 5 tumors (n = 39) was significantly worse than that of patients with segment 4 tumors (n = 43; 5-year overall survival rates, 69.8% versus 87.6%, p = 0.040; and 5-year recurrence-free survival rates, 58.4% versus 73.0%, p = 0.029). Segment 5 tumors were an independent factor for poor prognosis in multivariable Cox regression analysis, and tended to cause more pathologic mediastinal lymph node metastases than segment 4 tumors (12.8% versus 2.3%, p = 0.097). Compared with tumors in the other lobes, patients with segment 4 tumors demonstrated no significant difference in prognosis; however, patients with segment 5 tumors demonstrated a significantly and outstandingly worse prognosis than patients with other lobe tumors (5-year overall survival rates, 69.8% versus 82.2%, p = 0.020; and 5-year recurrence-free survival rates, 58.4% versus 71.4%, p = 0.0071). CONCLUSIONS: Patients with segment 5 tumors had a worse prognosis than patients with segment 4 and other lobe tumors. We speculate that is because segment 5 tumors cause more metastases to the mediastinal lymph nodes. Tumor location was an important prognostic factor for patients with right middle lobe lung cancer.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Handa Y, Tsutani Y, Ikeda T, et al. Reassessment of Right Middle Lobe Lung Cancer: Comparison of Segments 4 and 5 Tumors. Ann Thorac Surg. 2018. PMID: 29329989. doi:10.1016/j.athoracsur.2017.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。